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Abstract
Although iron is an essential element for
life, an excessive amount may become
extremely toxic both for its ability to generate
reactive oxygen species, and for the lack in
humans of regulatory mechanisms for iron
excretion. Chelation therapy has been intro-
duced in clinical practice in the seventies of
last century to defend thalassemic patients
from the effects of iron overload and, in spite
of all its limitations, it has dramatically
changed both life expectancy and quality of life
of patients. It has to be considered that the
drugs in clinical use present some disadvan-
tages too, this makes urgent new more suit-
able chelating agents. The requirements of an
iron chelator have been better and better
defined over the years and in this paper they
will be discussed in detail. As a final point the
most interesting ligands studied in the last
years will be presented.
Introduction
Although iron is an essential element for
life, an excessive amount may become
extremely toxic for the human body both for its
ability to generate reactive oxygen species
(ROS), and for the lack in humans of regulato-
ry mechanisms for iron excretion.1 Human
protection from iron induced damages involves
the degradation of H2O2 to water and oxygen by
the enzymes glutathione peroxidase and cata-
lase, the regulation of total unbound iron by
iron binding proteins to prevent hydroxyl radi-
cal formation, and the interruption of the radi-
cal chain reactions by radical scavengers. In
situations of iron imbalance however iron, no
more bound to proteins, is involved in redox
reactions leading to ROS generation; whenev-
er these situations exceed the antioxidant
defense of the organism, oxidative tissue dam-
age occurs,2 as in the case of hemochromatosis
and b-thalassemia (transfusion induced iron
overload). Chelation therapy was introduced in
clinical practice in the seventies of last century
to defend thalassemic patients from the toxic
effects of iron overload. Among the numerous
tasks of iron chelating agents, deeply dis-
cussed in several reviews,3-8 the main ones
consist in creating a favorable equilibrium
between transfusional iron assumed by
patients and that excreted in a chelated form,
in protecting against the circulating non trans-
ferrin bound iron which via Fenton reaction
easily leads to ROS production, and in scav-
enging iron stores from organs and tissues in
which exert their toxic action. The quantifica-
tion of iron stores in tissues can be accom-
plished by iron determination in liver
biopsies,9,10 or by magnetic resonance imag-
ing11 or by superconducting quantum interfer-
ence device magnetic susceptibility.12,13
The first used iron chelator has been desfer-
oxamine (DFO): this chelating agent, in spite
of all its limitations, has dramatically changed
both life expectancy and quality of life of
patients preventing the complications of iron
overload;14,15 as stated by Bernhardt7 the b-tha-
lassemic patients now in their 50’s … are living
proof of the value of this drug. The principal
drawbacks of desferoxamine are the lack of
oral activity, its high cost and the low compli-
ance. The joined research efforts of clinicians,
biochemists and chemists to improve the
knowledge of iron metabolism and of the req-
uisites of iron chelators has led to the intro-
duction in clinical use of two new oral chela-
tors deferiprone (DFP) and deferasirox (DFX)
(Figure 1) at the beginning of this century.
These drugs are extremely useful in the treat-
ment of iron overload, but they too present
some disadvantages, which make urgent the
need of new chelating agents more suitable
from a clinical point of view.2,6 In the Novartis
advices for DFX16 a warning is reported against
renal toxicity of this drug: Exjade can cause
acute renal failure, fatal in some patients and
requiring dialysis in others. Postmarketing
experience showed that most fatalities occurred
in patients with multiple comorbidities and
who were in advanced stages of their hemato-
logical disorders. According Hider17 DFX,
although able to readily enter the cells because
of its lipophilicity, forms at physiological pH a
negatively 3- charged iron complex that cannot
easily efflux from cells. This feature of iron
complex could explicate the nephrotoxic
effects of DFX. The formation of stable poly-
meric complexes with Zn2+ can further con-
tribute to toxic action of DFX. The notably high
pZn of DFX (9.44), larger than those of DFO
(6.01) and DFP (6.24), has to be remarked. 
In the last seven years a number of papers
were published on the comparison of cost
effectiveness of chelation therapy in transfu-
sion dependent thalassemia patients.18-22 The
common results for the US18 and UK19,21 health-
care system perspectives on the cost effective-
ness of oral DFX vs infusional DFO suggest
that DFX is cost effective compared to standard
chelation with DFO, while a different conclu-
sion is reached by Luangasanatip et al.20 in
Thailand. The two studies that perform a cost
analysis of DFP20,22 both suggest that DFP is the
most cost-effective cure for the treatment of
iron overload in b-thalassemia patients.
The design of new improved iron chelators
must take into account specific chemical prop-
erties.
The requirements of an iron chelator, better
and better defined over the years, can be out-
lined as:
- Favorable toxicity profile of chelating agent
and of its complexes;
- Stability of its complexes, higher than that
with endogenous ligands;
- Selectivity toward iron;
- Suitable redox potential of complexes;
- It should not be transformed into inactive
metabolites in the body;
- Good intestinal absorption and good
bioavailability to the target cells;
- Fast kinetic exchange of iron between
chelator and endogenous ligands; 
- Factors favoring excretion of the formed
complexes;
- It must not disturb the metabolic metal
homeostasis in the body fluids.
Further issues govern the suitability of an
iron chelator, as its cost and the patient com-
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pliance with its mode of administration. The
principal chemical requirements will be dis-
cussed in detail in the following sections, and
as a final point we will present some of the
most interesting ligands studied in the last
years.
Stability of the complexes
The necessary property of a chelating agent
is the stability of its complexes that must be
entirely formed before their excretion.
Depending on the number of the coordinating
groups which can bind a given metal ion at the
same time a chelator can be classified as
bidentate, tridentate and so on. The number of
the formed complexes and their stoichiome-
tries are determined by the denticity of the lig-
and. Hexadentate chelators are ideal for FeIII,
since they form only 1:1 complexes, while
lower denticity ligands form complexes of vari-
able stoichiometry, in amounts depending on
total ligand concentration and on metal/ligand
ratio. Lower stoichiometry iron complexes are
sometimes dangerous, for example they do not
avoid the reduction of FeIII to FeII leading to
ROS production via Fenton reaction. In con-
trast, bidentate and tridentate ligands may be
favored with respect to hexadentate chelators,
since they can be orally active for their lower
molecular weight. Oral activity is a highly
requested property of a drug: it cuts therapy
costs and increases the tolerability by the
patients.
A metal-ligand system is completely deter-
mined from the thermodynamic point of view
when its speciation model is known on the
basis of the stoichiometry and of the stability
constants of the formed species. Each com-
plex-formation reaction in a system containing
a metal ion M, a ligand L and the proton H is
described by the general equation:
(1)
and the corresponding formation constant, at
given temperature and ionic strength, is given
by:
(2)
where charges and coordinated solvent mole-
cules are omitted for simplicity. The terms in
square brackets are the molar concentrations
of the complex and of the free components; the
coefficient r assumes negative values when
the number of protons released from the lig-
and is higher than the number of protons
released in absence of metal ion, or when
hydroxylated species are formed.
Actually the real effective binding capacity
of a ligand cannot be directly inferred from the
stability constant, but it depends on a variety of
factors, the principal ones being the competi-
tion between metal and proton for the same
basic sites on the ligand, and the stoichiome-
try of the formed complexes. This real efficacy
is generally evaluated by parameter pM,
defined as –log[M] at [M]Tot = 1×10–6 M and
[L]Tot = 1×10–5 M at pH 7.4, where [M] is the
concentration of free metal ion and [M]Tot and
[L]Tot are the total concentrations of metal and
ligand, respectively. Iron chelators are normal-
ly compared on the basis of pFe values calculat-
ed from data at 25°C and 0.1 M ionic strength.
A pFe value >20 is required for efficiently scav-
enge iron from biological matrices. Some con-
ventional ways of calculating this value have to
be remembered, which, if not properly used,
can produce misleading results: in the model
used for the calculation of pFe the protonation
constants of the ligand and the formation con-
stants of all formed complexes have to be taken
into account, but the hydroxide formation con-
stants must not be considered, otherwise all
the ligands whose pFe is lower than that due to
the hydroxide formation, should result in a
similar pFe.
Effect of substituent
Interesting good linear correlations are
found when the protonation constants and the
iron complex formation constants of given
classes of ligands are considered. In particular,
examining the protonation and the stability
constants of pyridinones, reported in Table 1,23-26
good linear correlations are found between the
first protonation constant and the formation
constants log K11, log K12 and log K13 relative to
FeL, FeL2 and FeL3 complexes respectively, as
well as with the second protonation constant
log K2 (Figure 2A). 
These correlations are a clear indication
that the same properties determine proton and
iron binding. If one assumes that the log K1
values of pyridinone ligands can be modulated
by proper substituents, the log K2 and log K11,
log K12, log K13 values, also determined by the
effect of substituents, can be estimated by the
                             Clinical study
Figure 1. Formulas of the three iron chelating agents currently in
use.
Figure 2. A) The formation constants log K11 (°), log K12 (Ø)
and log K13 (▲) (relative to the complexes FeL, FeL2 and FeL3,
formed between ironIII and the pyridinones in Table 1) and the
second protonation constant log K2 () are reported vs the first
protonation constant log K1. B) pFe calculated from the set of
constants obtained as a function of log K1. (Reprinted from
Coordination Chemistry Reviews, Vol 252, Crisponi G., Remelli
M., Iron chelating agents for the treatment of iron overload,
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parameters of the above straight lines. These
values allow to evaluate the pFe values of sub-
stituted pyridinones as a function of log K1,
reported in Figure 2B.
The main feature of Figure 2B is the break
point that can be observed at log K1 7.4. This
implies that, when starting from a pyridinone
ligand characterized by a pK1 <7.4, a sub-
stituent that increases the pK1 value till to 7.4,
and all the related constants, has the effect of
increasing the pFe. On the contrary, when
starting from a ligand with pK1 >7.4, an
increase of the pFe can be obtained introduc-
ing substituents whose inductive and reso-
nance effects lead to a decrease of pK1 till to
7.4. The effect of pK1 in determining the pFe
value has been also remarked by Piyamangkol
et al.27 These authors described a number of 2-
and 6-amido-3-hydroxypyridin-4-ones, all char-
acterized by lower pKa values than that of
deferiprone, because of the inductive effect of
the amido group. Moreover, the pKa values of 1-
nonsubstituted pyridinones containing the 3-
hydroxy group are dramatically lower than
those of the corresponding 1-alkyl analogues.
This is due to a strong hydrogen bond between
the 2-amido function and the 3-oxygen anion,
stabilizing the anion. The pFe values of this
group of molecules result higher than that of
deferiprone as a consequence of the decreased
proton competition.
Selectivity toward iron
Metal selectivity is of paramount impor-
tance in the chemical design of iron chelators
for clinical application. Iron chelating agents
can be designed for either the FeII or FeIII oxi-
dation states. High-spin FeIII, a spherically
symmetrical tripositive cation of radius 0.65A°,
classified as a hard metal ion on the basis of
its high charge density, forms the most stable
complexes with hard ligands, such as those
containing charged oxygen atoms. In contrast,
FeII has a relatively low charge density and
prefers ligands characterized by soft donor
atoms. Ligands for FeII maintain a considerable
affinity for other bivalent metal ions, such as
CuII and ZnII, of biological relevance, so an FeII-
selective ligand is not realistic. On the con-
trary, FeIII-selective ligands, based on oxy-
anions form more stable complexes with triva-
lent cations than with divalent cations. Since
trivalent cations, as AlIII and GaIII, are not
essential for living organisms FeIII is selective-
ly complexed by iron chelators in a biological
environment. 
The interaction of chelating agents with
metal ions besides the toxic target one can be
determinant for the drug bioavailability and for
possible side effects. For this reason the rigor-
ous determination of the thermodynamic
parameters of the complexes with the main
endogenous bivalent metal ions, such as Cu,
Zn, Ca, Mg, has to be performed at standard-
ized conditions representative of the biological
fluid. 
Suitable redox potential of complexes
As pointed out in a previous section, the
toxic action of a redox-active metal ion as FeIII
depends on the formation of reactive oxygen
species that cause remarkable injuries to tis-
sues and organs.28,29 To prevent ROS formation
in the organism, the quantity of unbound iron
is limited by iron binding proteins.2
Nevertheless, iron can be mobilized from these
proteins in iron imbalance conditions, and in
such situations takes part in redox reactions
and generates ROS. Whenever these events go
beyond the antioxidant protection, oxidative
damages occur. In such cases iron redox
potential can be controlled by making use of
proper chelating agents, which avoid ROS pro-
duction. Siderophores molecules, with high
selectivity for FeIII, prevent redox cycling of
iron at biological conditions. On the contrary,
when nitrogen based ligands are used, charac-
terized by lower redox potentials, coordinated
iron is no more protected and can be enzymat-
ically reduced. In the review of Bernhardt7 the
cyclic voltammetry results for the iron com-
plexes with desferoxamine, deferiprone and
deferasirox are presented and discussed. All
the presented values indicate that the ferrous
oxidation state is inaccessible to biological
reductants in the presence of these three
chelating agents.
The redox potential dependence on the rela-
tive affinities for FeII and FeIII, as well as on pH,
was discussed by Boukhalfa and Crumbliss.30
Moreover, the complexation effects of hydrox-
ypyridinones on the redox properties of iron
with were thoroughly examined by Merkofer et
al.;31,32 also in this case the strong binding of
FeIII by this family of chelators prevents redox
cycling.
Formation of inactive metabolites in the body
Among the three iron chelators nowadays in
clinical use, deferoxamine is poorly metabo-
lized via transamination, b-oxidation, decar-
boxylation and N-hydroxylation.33
Deferiprone has a relatively short half-life,
<2 h,34 and a high first-pass effect due to glu-
curonidation. The resulting deferiprone glu-
curonidate metabolite cannot chelate iron,
being one of the two binding groups unavail-
able, and it is excreted into the urine through
the kidneys together with the complex FeIII-
deferiprone. Further minor metabolites are 3-
hydroxymethyl-1,2-dimethylpyridin-4-one and
2-hydroxymethyl-3-hydroxyglucronate-1-
methylpyridin-4-one.35 It has to be remarked
that the high doses required in deferiprone
clinical treatment mainly depend on glu-
curonidation effect.
The third chelator in use, deferasirox, is
excreted for 87% as unchanged drug, and 10%
as iron-complex in the feces. The 8% of the
dose is excreted by kidneys mainly as glu-
curonide. Further minor metabolites of
deferasirox are 5-hydroxydeferasirox and 5’-
hydroxydeferasirox.36
Good intestinal absorption and good bioavailability 
According Hider37 the three main factors
governing diffusion through biological mem-
branes are molecular size, lipophilicity and net
charge. In particular the molecular weight of
drugs to be absorbed in the human gut should
not exceed 500 Da. Lipophilicity is generally
estimated by the water-octanol partition coeffi-
cient (P). These factors have been proposed by
Lipinski et al.38 to evaluate membrane perme-
ability by a four parameter analysis. According
these authors a good absorption is likely when:
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Table 1. Protonation constants (log K1, log K2) and iron complex formation constants
(log K11, log K12 and log K13) for some pyridinones.
Ligand                                               Log K1       Log K2     Log K11      Log K12     Log K13    Ref.
1-Hydroxy-2- pyridinone                                  5.86                1.2              10.61                9.5                 7.1             23
1-Hydroxy-2- pyridinone                                  5.78                 --                10.3                 9.0                 7.6             24
3-Hydroxy-4- pyridinone                                  9.01               3.34              14.2                11.6                9.3             24
1,2-Dimethyl-3-hydroxy-4- pyridinone          9.82               3.66             15.01              12.3               10.1            25
1,2-Diethyl-3-hydroxy-4- pyridinone             9.93               3.81             15.21             11.76              9.78            26
This Table is reprinted from Coordination Chemistry Reviews, Vol 252, Crisponi G., Remelli M., Iron chelating agents for the treatment of
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i) molecular weight <500 Da; ii) log P<5; iii)
less than 10 hydrogen bond donors (sum of OH
and NH groups) are present in the drug; iv)
less than 10 hydrogen bond acceptors (sum of
O and N atoms) are present in the drug. 
Fast kinetic exchange of iron between chelator and endogenous ligands 
The behavior of a chelator depends, besides
the thermodynamics of complex formation, on
kinetic factors, connected to: i) degradation of
the chelating agent; ii) complex formation
between the chelator and the free metal ion in
the plasma; and iii) exchange reaction
between the metal bound to endogenous mole-
cules and the chelating agent.
i) Many chelating agents are metabolized in
the body to species that loose the chelating
properties of the parent molecule. These reac-
tions can be very different, from the glu-
curonidation of hydroxypyrydinones, to the
acetylation of Trien, or the formation of –S-S-
bonds between BAL and SH-containing lig-
ands. The correct choice of drug administra-
tion becomes of vital importance when this
kind of metabolic transformation is rapid, as
for example the subcutaneous infusion of
deferoxamine.
ii) The circulating toxic iron ions in plasma
are generally bound by different endogenous
molecules, ranging from large macromolecules
as transferrin to low molecular weight ligands
as citrate.
iii) The kinetic of the exchange reaction
between the ferric ion bound to endogenous
molecules and the chelators depends on a vari-
ety of factors, among which the structure, the
denticity and the size of the chelator. The
knowledge of the different kinetic behaviors of
the chelators in use has conducted to improved
schemes of therapy. In case of iron overload
theraphy, in which a more than 30 years expe-
rience has been accumulated on deferoxamine
action, and at least 20 years for deferiprone,
the knowledge of the differences in organ dis-
tribution and bioavailability, in target biomole-
cules and in kinetic and thermodynamic prop-
erties, has lead to a combination therapy in
which the two chelators exert a synergistic
action.39,40
Recent research achievementson iron chelating agents
In this section a surely not exhaustive sur-
vey of recent progresses in the study of new
iron chelators will be presented. A number of
new ligands appeared in literature in the last
10 years, reporting thorough studies of com-
plex formation equilibria and, in some cases,
biological evaluations. Particular attention has
been paid to 3-hydroxy-4-pyridinone (3,4-HP)
ligand family. The 3,4-HPs are mono-anionic
N-heterocyclic molecules that bind FeIII with
the two oxygen atoms (bidentate {O,O} chela-
tors) with high affinity. This family of ligands
can be easily extra-functionalized with the aim
of improving their properties, above all the
bioavailability and the chelating ability. The
group of Hider37,41 has proposed a variety of
bidentate or polydentate 3,4-HP chelators. In
particular they synthesized and studied the
chemical properties of different 2- and 6-
amido-3-hydroxypyridin-4-ones; it is interest-
ing to remark that all these ligands exhibit
lower pKa values than deferiprone due to the
inductive effect of the amido group. These
lower pKa’s led to a decreased proton competi-
tion, so to better chelating properties in com-
parison with the parent deferiprone. Some lig-
ands of the HP family were also studied for the
treatment of toxicity of other hard metal ions:
aluminium, by Santos et al.42,43 and plutonium
by Fukuda.44 A number of tetradentate 3,4-HP
chelators have been studied by the group of
Santos;45,46 in one case two 3,4-HP chelating
moieties were connected by an iminodiacetic
acid (IDA) scaffold, with a 1,4-disubstituted
arylpiperazine on the nitrogen atom in the
linker. The same authors also presented: 
- Two hexadentate ligands, based on the KEMP
acid scaffold to which three 3-hydroxy-4-
pyridinone chelating moieties are attached
via two differently sized spacers, the tris-
hydroxypyridinone based compounds
KEMPPr(3,4-HP)3 and MPBu(3,4- HP)3.47
These ligands are very strong chelating
agents not only towards iron but also for
group III metal ions, with potential clinical
applications in metal chelation therapy. 
- Two new tris(3-4-HP) hexadentate chelators,
NTA(BuHP)3 and NTP(PrHP)3, in which the
three HP units were connected by nitrilotri-
acetic acid (NTA) and nitrilotripropionic
acid (NTP). Their iron complex formation
ability has been studied in solution and
their scavenging properties from overloaded
animals assayed in vivo. A very strong
chelating affinity for Fe must be remarked
[pFe = 27.9 NTA(BuHP)3; pFe = 29.4 for
NTP(PrHP)3].48
Further families of ligands have been con-
sidered as chelators for trivalent metal ions.
Biaso et al.49 presented two tripodal molecules,
O-TRENSOX, formed by three 8-hydroxy-5-sul-
fonate-quinoline anchored on tris(2-
aminoethyl)amine (TREN), as well as analo-
gous triscatechol derivatives TRENCAMS.
Impressive pAl values 20.0 and 26.2 for O-
TRENSOX and TRENCAMS respectively were
reported. Numerous studies on the design,
synthesis and complex formation equilibria of
variously substituted hydroxypyridinecar-
boxylic acids have been presented by the group
of Di Marco: these ligands are characterized by
two coordinating groups (–OH and –COOH) in
various positions (2,3; 3,2; 3,4; 4,3) and differ-
ently methylated.50-55 A study of our group on
bisphosphonate ligands showed their high
efficiency as iron chelating agents, reaching
pFe values higher than that of deferiprone.56 To
further improve bisphosphonate chelating
properties the conjugation with other strong
coordinating groups was proposed. Ding et al.57
synthesized catechol-bisphosphonate conju-
gates and Bailly et al.58 mixed bisphosphonate-
hydroxypyridinonate compounds. With both
kinds of ligands the too short linker prevented
simultaneous tetradentate coordination.59,60
Fox and Taylor61 experimented an interesting
iron chelator, formed by two kojic acid units
linked by a methylene group, for the in vitro
mobilization of ferritin-bound iron, and proved
its high efficacy. This ligand forms stable iron
dinuclear complexes, characterized by the
extremely high pFe value 20.5.62 On the basis
of this interesting chemical result we designed
and synthesized a variety of chelators based on
two KA units joined by different linkers.63-65 In
particular those based on a –CH2-NR-CH2-
linker form Fe2L3 complexes in which the three
ligands completely satisfy the coordination
sphere of two iron ions. The relatively low
molecular weight (340-450 Da) characterizes
them as possible oral chelators, and the many
chances of modulating their binding ability
working on proper substituents in the KA units
and in the linker offer good perspectives. 
Many tetradentate ligands have been inves-
tigated to date as possible FeIII chelators for
oral use. In order to completely saturate the six
coordination positions on ferric ion, the den-
ticity of these ligands requires formation of
polynuclear species, which are invariably
found in these systems. In particular, the most
common polynuclear complex is the dimer
Fe2L3, with a charge depending on ligand struc-
ture. An especially high affinity for the ferric
ion has been found by Santos et al.66 concern-
ing the new bis(3-hydroxy-4-pyridinone) deriv-
ative of iminodiacetic acid, imino-bis(acetyl(1-
(3-aminopropyl)-3-hydroxy-2-methyl-4-pyridi-
none)), IDAPr(3,4-HP)2.
The calculated pFe value is 25.8, of the
same order of magnitude as that of DFO.
However, in the case of IDAPr(3,4-HP)2, up to
eight complex species form in the explored
pH range (0.4-9), and their relative amount at
a defined pH (e.g. 7.4) depends on the total
concentration of both the metal ion and the
ligand.
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Conclusions
In the last thirty years the chemical
research has been deeply involved in the syn-
thesis of a large variety of iron chelators
according to the structural requisites for their
introduction in clinical practice. Despite the
significant improvements made in the cure of
iron overload with the introduction of
deferiprone and deferasirox, and of combined
chelation therapy, the clinical results have not
been completely satisfactory for the various
drawbacks presented by these chelators. The
failure to find the ideal iron chelator can be
ascribed to inherent difficulties deriving from
the biological and clinical restraints. 
We think that the large research efforts on
these topics have in any way created a large
progress in this field, above all with a deeper
knowledge of iron metabolism, drug targets,
drug absorption mechanisms, relationships
between structure and physical-chemical prop-
erties, and basic requirements for the different
clinical purposes.
We hope that a continuous dialogue among
chemists and clinicians, and an ample support
to the research in this field, will lead to the
common target of prolonging survival and
improving the quality of life of iron-loaded
patients. 
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